机构:[1]Department of Medicine, Shanghai Clinical Research Center, Shanghai, China[2]Department of Traditional Chinese Medicine, Changhai Hospital, Naval Medical University, Shanghai, China[3]Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China[4]Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China[5]Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China[6]Chongqing University Cancer Hospital, Chongqing, China[7]Department of Oncology, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China大德路总院肿瘤科广东省中医院[8]The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing, China[9]Department of Oncology Diagnosis and Treatment, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
Integrative oncology has developed for about 20 years in some countries; however, integrative oncology is still a relative new term for most China's oncologists. Thus, it is essential to summarize the experience and expertise, share details of differing existing models and discuss future perspectives to help define and guide practice in integrative oncology in China. This study presents a summary of the basic characteristics, status, and challenges of integrative oncology in China, and also reports on China's integrative physicians' service delivery, clinical practice and research patterns of integrative oncology by an online national survey, including 405 oncologists. It is easy for cancer patients to access to integrative therapies in China. Public funding is sufficient for integrative oncology in China, and services are often provided through general hospitals and academic hospitals. Most (95.3%) of oncologists showed a positive attitude toward the development of integrative oncology. More than half (55.6%) of the oncologists worried about the influence on integrative oncology of COVID-19, especially for routine treatment, follow-up and holding seminars. We found that integrative oncology in China has swiftly developed in recent years. However, we suggest that standard diagnosis and treatment patterns and national professional guidelines should be set up as soon as possible.
基金:
National Key Research and
Development Program of China (No. 2017YFC1700604).
第一作者机构:[1]Department of Medicine, Shanghai Clinical Research Center, Shanghai, China
共同第一作者:
通讯作者:
通讯机构:[7]Department of Oncology, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China[8]The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing, China[9]Department of Oncology Diagnosis and Treatment, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China[*1]Department of Oncology Diagnosis and Treatment, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, 100091, China.[*2]The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing, Jiangsu, 210093, China.[*3]Department of Oncology, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, 510120, China.
推荐引用方式(GB/T 7714):
Yang Geliang,Zhang Huiqing,Xu Yun,et al.Basic Characteristics, Status, and Challenges of Integrative Oncology in China[J].INTEGRATIVE CANCER THERAPIES.2021,20:doi:10.1177/15347354211063504.
APA:
Yang, Geliang,Zhang, Huiqing,Xu, Yun,Zhao, Aiguang,Shu, Peng...&Yang, Yufei.(2021).Basic Characteristics, Status, and Challenges of Integrative Oncology in China.INTEGRATIVE CANCER THERAPIES,20,
MLA:
Yang, Geliang,et al."Basic Characteristics, Status, and Challenges of Integrative Oncology in China".INTEGRATIVE CANCER THERAPIES 20.(2021)